Current Cardiology Reports

, Volume 4, Issue 6, pp 488–493 | Cite as

Hypertriglyceridemia and risk of coronary heart disease

  • John E. Hokanson


Mounting evidence indicates that elevated triglyceride level is a risk factor for coronary heart disease (CHD). The role of triglyceride as a causative agent for CHD is less clear. Hyper-triglyceridemia is frequently associated with a set of complex metabolic abnormalities, including low high-density lipoprotein cholesterol, small dense low-density lipoprotein, central obesity, insulin resistance, and type 2 diabetes. Understanding the physiologic processes that lead to the metabolic disturbances associated with hypertriglyceridemia is essential in investigating the effect of triglyceride on CHD risk.


Triglyceride Familial Combine Hyperlipidemia Lipoprotein Lipase Gene Lipoprotein Lipase Deficiency Paris Prospective Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Gofman JW, DeLalla O, Flazier F, et al.: The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary disease. Plasma 1954, 2:413–483.Google Scholar
  2. 2.
    Albrink M, Mann E: Serum triglycerides in coronary artery disease. Arch Intern Med 1959, 103:4–8.Google Scholar
  3. 3.
    Brown DF, Kinch SH, Doyle JT: Serum triglycerides in health and in ischemic heart disease. N Engl J Med 1965, 273:947–952.PubMedCrossRefGoogle Scholar
  4. 4.
    Hulley SB, Rosenman RH, Bawol RD, Brand RJ: Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 1980, 302:1383–1389.PubMedCrossRefGoogle Scholar
  5. 5.
    Hokanson JE, Austin MA: Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213–219.PubMedCrossRefGoogle Scholar
  6. 6.
    Abdel-Maksoud MF, Hokanson JE: The complex role of triglyceride in cardiovascular disease: both independence and synergy with HDL cholesterol. Semin Vasc Med 2002, 2:325–333. An update of a meta-analysis of triglyceride and cardiovascular disease that includes over 75,000 subjects. Triglyceride (1 mmol/L) predicts a 30% increase in men and a 70% increase in women.PubMedCrossRefGoogle Scholar
  7. 7.
    Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029–1036. Recognized the noncontinuous relationship between triglyceride and incidence of CHD from 2906 men in the Copenhagen Male Study. Men with triglyceride levels greater than 222 mg/dL have a lower risk of CHD than men with triglycerides between 142 and 222 mg/dL.PubMedGoogle Scholar
  8. 8.
    Assmann G, Schulte H, Funke H, von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998, 19(Suppl M):M8-M14.PubMedGoogle Scholar
  9. 9.
    Onat A, Sansoy V, Yildirim B: Which fasting triglyceride levels best reflect coronary risk? Evidence from the Turkish Adult Risk Factor Study. Clin Cardiol 2001, 24:9–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Cambien F, Jacqueson A, Richard JL, et al.: Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? The Paris Prospective Study. Am J Epidemiol 1986, 124:624–632.PubMedGoogle Scholar
  11. 11.
    Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328:1220–1225.PubMedCrossRefGoogle Scholar
  12. 12.
    Rhoads GG, Feinleib M: Serum triglyceride and risk of coronary heart disease, stroke, and total mortality in Japanese-American men. Arteriosclerosis 1983, 3:316–322.PubMedGoogle Scholar
  13. 13.
    Heyden S, Heiss G, Hames CG, Bartel AG: Fasting triglycerides as predictors of total and CHD mortality in Evans County, Georgia. J Chronic Dis 1980, 33:275–282.PubMedCrossRefGoogle Scholar
  14. 14.
    Iso H, Naito Y, Sato S, et al.: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001, 153:490–499. Demonstrated that elevated nonfasting triglyceride was a significant independent risk factor for coronary disease in Japanese subjects.PubMedCrossRefGoogle Scholar
  15. 15.
    Sharrett AR, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108–1113. Identified triglyceride as a predictor of CHD in black Americans. Tested for ethnicity by triglyceride interaction and found no significant difference in risk of CHD due to triglyceride between black and white subjects in the ARIC cohort.PubMedGoogle Scholar
  16. 16.
    Brunzell JD, Albers JJ, Chait A, et al.: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983, 24:147–155.PubMedGoogle Scholar
  17. 17.
    Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966, 34:679–697.PubMedGoogle Scholar
  18. 18.
    Castelli WP: Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992, 70:3H-9H.PubMedCrossRefGoogle Scholar
  19. 19.
    Brunzell JD, Schrott HG, Motulsky AG, Bierman EL: Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976, 25:313–320.PubMedCrossRefGoogle Scholar
  20. 20.
    Austin MA, McKnight B, Edwards KL, et al.: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000, 101:2777–2782.PubMedGoogle Scholar
  21. 21.
    Austin M, King M-C, Vranizan K, Krauss RM: The atherogenic lipoprotein phenotype (ALP): a proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495–506.PubMedGoogle Scholar
  22. 22.
    Hokanson JE, Brunzell JD, Jarvik GP, et al.: Linkage of lowdensity lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet 1999, 64:608–618.PubMedCrossRefGoogle Scholar
  23. 23.
    Hokanson JE: Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Curr Opin Lipidol 1999, 10:393–399.PubMedCrossRefGoogle Scholar
  24. 24.
    McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7–18.PubMedCrossRefGoogle Scholar
  25. 25.
    Holzl B, Iglseder B, Sandhofer A, et al.: Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency. Diabetologia 2002, 45:378–384. This article demonstrates that a genetic defect in triglyceride metabolism due to the LpL gene is associated with insulin resistance, and suggests a possible primary role for triglyceride in insulin resistance and type 2 diabetes.PubMedCrossRefGoogle Scholar
  26. 26.
    Pfeifer MA, Brunzell JD, Best JD, et al.: The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridemia. Diabetes 1983, 32:525–531.PubMedCrossRefGoogle Scholar
  27. 27.
    Junker R, Pieke B, Schulte H, et al.: Changes in hemostasis during treatment of hypertriglyceridemia with a diet rich in monounsaturated and n-3 polyunsaturated fatty acids in comparison with a low-fat diet. Thromb Res 2001, 101:355–366. Treatment of hypertriglyceridemia leads to improvement in hemostatic and inflammatory markers.PubMedCrossRefGoogle Scholar
  28. 28.
    Jonkers IJ, Mohrschladt MF, Westendorp RG, et al.: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002, 112:275–280. Treatment of hypertriglyceridemia leads to improvement in hemostatic and inflammatory markers.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • John E. Hokanson
    • 1
  1. 1.Department of Preventive Medicine & BiometricsUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations